Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Updated: Mar 6 2023

Oxaplatin

Indications
  • Colorectal Cancer (USA and Non-US)
  • Ovarian CA (Non-US)
Mechanisms
  • A third generation platinum compound.
  • Cell cycle-nonspecific with activity is all phases of the cell cycle.
  • Covalently binds to DNA with preferential binding to the N-7 position of guanine and adenine.
  • Produces DNA cross-links, both intrastrand (>90%) and interstrand (< 5%) that leads to the inhibition of of DNA synthesis and function as well as inhibition of transcription.
  • DNA mismatch repair enzymes are unable to recognize oxaliplatin DNA adducts
  • Binding to nuclear or cytoplasmic proteins may results in additional cytotoxic effects
Toxicity
  • Neurotoxicity: Peripheral sensory neuropathy with distal paresthesias, often triggered or exacerbated by cold. Acute dysthesias in the upper extremities and laryngopharyngeal region with episodes of difficulty breathing or swallowing usually observed within hours or 1-3 days after therapy.
  • Nausea and Vommiting
  • Diarrhea
  • Myelosuppression (mild thrombocytopenia, anemia more common than neutropenia)
  • Severe allergic reactions with facial flushing, rash, urticaria, bronchospasm, hypotension.
  • Renal toxicity: Rare
  • Ototoxicity: Rare
Resistance
  • Decreased drug accumulation
  • Increased DNA repair enzyme activity
 
Private Note

Attach Treatment Poll
Treatment poll is required to gain more useful feedback from members.
Please enter Question Text
Please enter at least 2 unique options
Please enter at least 2 unique options
Please enter at least 2 unique options